基本信息
浏览量:1
职业迁徙
个人简介
My research spans both type 1 and type 2 childhood diabetes.
The first aspect of my research relates to the prevention of type 2 diabetes (T2D) and its associated co-morbidities in youth with mental health conditions treated with atypical antipsychotic (AAP) medications. Since 2006, we have performed foundational research on AAPs and their metabolic sequelae in children / youth, established key partnerships and a platform for ongoing research, and created and implemented Canada’s first (and so far only) pediatric Provincial Mental Health Meta-bolic Program.
At the request of remote First Nations communities in BC, I have conducted diabetes screening and found high prevalence of pre-diabetes in youth residing in the region. This led to the program development of a modified, culturally appropriate Actions Schools! BC and Healthy Buddies program for implementation at three Tsimshian communities.
Further, in collaboration with Drs. Jean-Pierre Chanoine and Louise Masse, I led the evaluation of the Shapedown program at BC Children's Hospital. Shapdown is a multi-disciplinary, well-defined weight treatment/management program for children and adolescents with a family-focused intervention. I led the evaluation of this program’s effect on BMI, insulin resistance, metabolic syndrome, and examined its effect on changes in psychological outcomes, nutrition, and physical activity.
In the realm of type 1 diabetes (T1D), I am the Clinical Core Leader within the CIHR New Emerging Team in Childhood Autoimmunity. Immune white cells, such as cytotoxic T lymphocytes (CTL) and natural killer (NK) cells protect us from infections by killing infected cells. Conversely, defects in their function or regulation lead to autoimmune diseases such as T1D. I collaborate with Dr. Rusung Tan in trying to understand the defects in these cells in order to develop new therapies and prevention strategies for this disease. In addition I am the regional site lead and Vancouver Affiliate PI for TrialNET, an international, multi-centre network dedicated to the study, prevention and treatment of T1D.
The first aspect of my research relates to the prevention of type 2 diabetes (T2D) and its associated co-morbidities in youth with mental health conditions treated with atypical antipsychotic (AAP) medications. Since 2006, we have performed foundational research on AAPs and their metabolic sequelae in children / youth, established key partnerships and a platform for ongoing research, and created and implemented Canada’s first (and so far only) pediatric Provincial Mental Health Meta-bolic Program.
At the request of remote First Nations communities in BC, I have conducted diabetes screening and found high prevalence of pre-diabetes in youth residing in the region. This led to the program development of a modified, culturally appropriate Actions Schools! BC and Healthy Buddies program for implementation at three Tsimshian communities.
Further, in collaboration with Drs. Jean-Pierre Chanoine and Louise Masse, I led the evaluation of the Shapedown program at BC Children's Hospital. Shapdown is a multi-disciplinary, well-defined weight treatment/management program for children and adolescents with a family-focused intervention. I led the evaluation of this program’s effect on BMI, insulin resistance, metabolic syndrome, and examined its effect on changes in psychological outcomes, nutrition, and physical activity.
In the realm of type 1 diabetes (T1D), I am the Clinical Core Leader within the CIHR New Emerging Team in Childhood Autoimmunity. Immune white cells, such as cytotoxic T lymphocytes (CTL) and natural killer (NK) cells protect us from infections by killing infected cells. Conversely, defects in their function or regulation lead to autoimmune diseases such as T1D. I collaborate with Dr. Rusung Tan in trying to understand the defects in these cells in order to develop new therapies and prevention strategies for this disease. In addition I am the regional site lead and Vancouver Affiliate PI for TrialNET, an international, multi-centre network dedicated to the study, prevention and treatment of T1D.
研究兴趣
论文共 129 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
N. Wu,S. Wang,A. Brazeau, D. Chan, J. Mussa, M. El Keraby, M. Ell, M. Provost, L. Lepine,M. Nakhla,C. Panagiotopoulos, G. Mukerji,S. Butalia,M. Henderson,D. Da Costa,E. Rahme,K. Dasgupta
Canadian Journal of Cardiologyno. 10 (2023): S142-S142
Nancy Wu,Susan Joanne Wang,Anne-Sophie Brazeau,Deborah Chan,Joseph Mussa,Meranda Nakhla, Mariam Elkeraby, Maryna Ell,Melinda Prevost, Laurie Lepine,Constadina Panagiotopoulos,Geetha Mukerji,Sonia Butalia,Melanie Henderson,Deborah Da Costa,Elham Rahme,Kaberi Dasgupta
pubmed(2023)
Mandy Fisher,Gina Muckle,Bruce Lanphear,Tye E. Arbuckle,Joseph M. Braun,Angelika Zidek,Maria P. Velez,Nicole Lupien,Stephanie Bastien,Jillian Ashley-Martin,Youssef Oulhote,Michael M. Borghese,Mark Walker,Elizabeth Asztalos,Maryse F. Bouchard,Linda Booij,Mark R. Palmert,Katherine M. Morrison,Elizabeth A. Cummings,Karine Khatchadourian,Constadina Panagiotopoulos,Gord Glendon,Robin Shutt,Ammanie Abdul-Fatah,Kelsey Seal,William D. Fraser
Paediatric and perinatal epidemiologyno. 8 (2023): 719-732
Canadian Journal of Diabetesno. 5 (2022): 457-463.e1
Diabetesno. Supplement_1 (2022)
Journal of the Endocrine Societyno. Supplement_1 (2022)
Canadian Journal of Diabetesno. 7 (2021): S36
加载更多
作者统计
#Papers: 128
#Citation: 3015
H-Index: 30
G-Index: 53
Sociability: 6
Diversity: 3
Activity: 6
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn